<DOC>
	<DOCNO>NCT00050180</DOCNO>
	<brief_summary>This study examine whether particular type gene ( MDR1 ) body affect blood level two protease inhibitor , indinavir saquinavir , use treat people HIV . If blood level drug low high , may work well may cause side effect patient . This study determine MDR1 gene might affect absorption medicine . Healthy normal volunteer 18 50 year age may eligible study . Candidates screen medical history blood urine test . The blood test : - Routine laboratory value assess general health - HIV - MDR1 gene type - Amount P-glycoprotein ( protein make MDR1 gene ) T cell . Participants blood drawn three time , follow : - After one dose sedative midazolam ( Versed ( Registered Trademark ) ) : Participants take 8-milligram dose midazolam syrup mouth . Four hour later , single blood sample drawn needle arm vein . This part study assess efficiency certain enzyme involve metabolizing ( break ) indinavir saquinavir . - After four dos indinavir : About week take midazolam , participant take 800 mg indinavir ( two capsule ) 3 time day ( every 8 hour ) 1 day . The following morning come clinic , catheter ( flexible plastic tube ) place arm vein repeat blood draw . A blood sample drawn , fourth final dose indinavir give . Seven blood sample teaspoon collect catheter 8-hour period measure blood level drug . - After 10 dos saquinavir : About week last dose indinavir , participant start take 1,200 mg ( 6 capsule ) saquinavir soft-gelatin capsule 3 time day 3 day . On fourth day , participant come clinic . A catheter insert arm vein 4 teaspoon blood collect routine laboratory test measure saquinavir level . A urine sample also collect routine test . Participants receive tenth final dose saquinavir , eight blood sample teaspoon collect catheter 8-hour period .</brief_summary>
	<brief_title>Influence MDR1 Genotype Blood Levels Indinavir Saquinavir Healthy Volunteers</brief_title>
	<detailed_description>The expression P-glycoprotein , transporter protein present enterocytes well cell involve absorption distribution HIV protease inhibitor , link single nucleotide polymorphism ( SNP ) exon 26 MDR1 gene , C3435T . Individuals homozygous T allele reduce P-gp expression compare CC individual . Preliminary study investigator determine influence MDR1 genotype HIV protease inhibitor pharmacokinetics yield inconclusive result . The primary purpose study determine relationship , , MDR1 genotypes plasma concentration HIV protease inhibitor indinavir saquinavir . Secondary objective investigation ( 1 ) ass relationship CYP3A4 activity indinavir saquinavir exposure ( 2 ) characterize relationship , , P-gp expression lymphocyte surface MDR1 genotype . Up 150 subject screen enroll total 63 healthy volunteer ( 21 subject CC , TT , CT group ) . Each subject blood drawn P-gp expression analysis MDR1 genotyping screen . Next , subject receive oral midazolam 8 mg CYP3A4 phenotyping ; single blood sample collect 4 hour midazolam administration determination midazolam 1-hydroxymidazolam . Between 7 28 day midazolam administration , subject receive indinavir 800 mg every 8 hour one day single 800 mg dose next morning ( dose # 4 ) . Between 7 28 day indinavir administration , subject receive saquinavir soft-gel capsule 1200 mg three time daily 3 day single dose morning day 4 ( dose # 10 ) . Post-dose blood sample collect 8 hour follow dose # 4 indinavir dose # 10 saquinavir . Indinavir saquinavir pharmacokinetic parameter ( primarily AUC Cmax ) compare across MDR1 genotype group use ANOVA post-hoc testing . 1-hydroxymidazolam : midazolam ratio correlate indinavir saquinavir AUCs well compare across MDR1 genotype group . P-gp expression lymphocyte surface determine flow cytometry , quantify , compare across MDR1 genotype group . Data investigation determine whether MDR1 genotype influence protease inhibitor plasma concentration .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Males female age 18 60 year . 2 . Healthy medical history physical exam 3 . Laboratory value within establish guideline participation clinical study : AST le equal 2 time ULN ( upper limit normal ) ; Serum creatinine less equal ULN ; hemoglobin great equal 11 g/dL . 4 . Ability abstain ingest grapefruit grapefruit juice 72 hour prior , day midazolam phenotyping indinavir saquinavir administration . 5 . Negative serum pregnancy test female childbearing potential . 6 . Females childbearing potential able willing practice abstinence use effective method birth control Phase II study include oral contraceptive . EXCLUSION CRITERIA : 1 . Concomitant routine therapy prescription , counter , herbal , holistic medication , include oral contraceptive 30 day prior study participation . Subjects must oral contraceptive least 30 day prior blood collection Pgp expression analysis ; must also oral contraceptive least 30 day prior midazolam phenotyping , indinavir saquinavir administration . Intermittent ( PRN ) use acetaminophen nonsteroidal antiinflammatory medication ( i.e . ibuprofen ) allow study ; medication take prior , within 4 hour midazolam administration Day 0 . These medication take indinavir saquinavir administration blood sample pharmacokinetic analysis respective drug obtain . Subjects allow take multivitamin mineral , equivalent , daily desire . 2 . Inability obtain venous access sample collection . 3 . Presence Diabetes mellitus , Human immunodeficiency virus ( HIV ) infection , cardiac disease ( hypertension ; congestive heart failure etc . ) , renal disease ( chronic acute renal failure insufficiency ) , respiratory disease ( asthma require chronic treatment ; chronic obstructive pulmonary disease ) condition may interfere interpretation study result best interest subject opinion investigator . 4 . Positive pregnancy test breastfeed female . 5 . The presence persistent diarrhea malabsorption would interfere subject 's ability absorb drug . 6 . Drug alcohol use may impair safety adherence . 7 . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) indinavir , saquinavir midazolam . 8 . Inability unwillingness female childbearing potential , use nonhormonal ( barrier ) method contraception throughout study ( e.g . condom diaphragm etc. ) . 9 . Current cigarette smoker regular smoker within past 6 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 3, 2012</verification_date>
	<keyword>P-Glycoprotein</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Antiretrovirals</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>Drug Transporters</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>